Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 29 P702

ICEECE2012 Poster Presentations Diabetes (248 abstracts)

Simultaneous Pancreatic Kidney Transplant Experience in The South West of Ireland between 2001–2011

D. Slattery , T. Hussain , M. O’Cathail , A. Tuthill , W. Plant & D. O’Halloran


Cork University Hospital, Cork, Ireland.


Introduction: Simultaneous pancreatic kidney transplantation (SPK) has become the therapy of choice in patients with type 1 diabetes mellitus (DM) and end stage diabetic nephropathy.

Methods: An analysis was performed of type 1 diabetic patients with end stage diabetic nephropathy who received treatment with SPK between 2001–2011 in the South West of Ireland, population 663,176 with a prevalence of type 1 DM in this region estimated to be 0.3%. Data was obtained from the South West of Ireland nephrology database.

Results: Between 2001 and 2011, 35 type 1 diabetics with end stage diabetic nephropathy were treated in the South West of Ireland. 14 have undergone SPK and 8 have undergone kidney transplant alone. 3 patients are currently awaiting SPK and 3 awaiting kidney transplant alone. Seven out of 35 died while receiving dialysis. The mean age of the SPK group was 41 years ±9.80. The mean duration of disease at time of SPK was 29.58 years ±9.48. The average waiting time from being placed on the transplant pool to transplantation was 19 months ±12.38. No mortality was reported post SPK. There was loss of pancreatic allograft in 4 patients: 2 in the immediate post-operative period (< 10 days post op), 1 at 9 years post-transplant and 1 at ten years post-transplant. The mean pre-operative HbA1C was 9.6% and 12 months post-operatively was 6.2% in the 12 functioning pancreatic allografts. Twelve month mean post-operative GFR in the 14 patients was 55mL/min/1.73m2.

Conclusion: SPK is the treatment of choice in type 1 diabetics with end stage diabetic nephropathy. SPK is performed in a single centre in Ireland, with 12 month pancreas allograft survival rates in our cohort of 79% which is comparable to international centres of excellence.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector

Volume 29

15th International & 14th European Congress of Endocrinology

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.